Analysts have mixed views on the stock, with 0 analysts rating it as a “buy,” 0 as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for SLRN is 61.01M, and currently, short sellers hold a 13.03% ratio of that float. The average trading volume of SLRN on April 19, 2024 was 1.29M shares.
SLRN) stock’s latest price update
The stock of Acelyrin Inc (NASDAQ: SLRN) has decreased by -2.79 when compared to last closing price of 5.02. Despite this, the company has experienced a -15.28% fall in its stock price over the last five trading sessions. Zacks Investment Research reported 2024-03-21 that ACELYRIN (SLRN) posts positive proof-of-concept data from a phase I/II study evaluating its pipeline candidate, lonigutamab, for treating thyroid eye disease. Stock gains.
SLRN’s Market Performance
Acelyrin Inc (SLRN) has seen a -15.28% fall in stock performance for the week, with a -38.69% decline in the past month and a -18.26% plunge in the past quarter. The volatility ratio for the week is 7.28%, and the volatility levels for the past 30 days are at 7.28% for SLRN. The simple moving average for the past 20 days is -22.98% for SLRN’s stock, with a -59.60% simple moving average for the past 200 days.
Analysts’ Opinion of SLRN
Many brokerage firms have already submitted their reports for SLRN stocks, with Wells Fargo repeating the rating for SLRN by listing it as a “Equal Weight.” The predicted price for SLRN in the upcoming period, according to Wells Fargo is $11 based on the research report published on December 13, 2023 of the previous year 2023.
Citigroup, on the other hand, stated in their research note that they expect to see SLRN reach a price target of $8. The rating they have provided for SLRN stocks is “Neutral” according to the report published on December 08th, 2023.
Morgan Stanley gave a rating of “Equal-Weight” to SLRN, setting the target price at $19 in the report published on September 13th of the previous year.
SLRN Trading at -33.46% from the 50-Day Moving Average
After a stumble in the market that brought SLRN to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -83.67% of loss for the given period.
Volatility was left at 7.28%, however, over the last 30 days, the volatility rate increased by 7.28%, as shares sank -41.35% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -38.23% lower at present.
During the last 5 trading sessions, SLRN fell by -15.28%, which changed the moving average for the period of 200-days by -76.10% in comparison to the 20-day moving average, which settled at $6.16. In addition, Acelyrin Inc saw -34.58% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at SLRN starting from Lin Shao-Lee, who sale 9,961 shares at the price of $6.63 back on Apr 01 ’24. After this action, Lin Shao-Lee now owns 1,577,374 shares of Acelyrin Inc, valued at $66,024 using the latest closing price.
Lin Shao-Lee, the Chief Executive Officer of Acelyrin Inc, sale 15,701 shares at $7.60 during a trade that took place back on Feb 20 ’24, which means that Lin Shao-Lee is holding 1,587,335 shares at $119,403 based on the most recent closing price.
Stock Fundamentals for SLRN
The total capital return value is set at -0.72.
Based on Acelyrin Inc (SLRN), the company’s capital structure generated -0.0 points at debt to capital in total, while cash flow to debt ratio is standing at -91.19.
Currently, EBITDA for the company is -254.86 million with net debt to EBITDA at 0.71. The liquidity ratio also appears to be rather interesting for investors as it stands at 8.65.
Conclusion
To put it simply, Acelyrin Inc (SLRN) has had a bad performance in recent times. Analysts have a mixed opinion on the stock, with some rating it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
